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CHAPTER 1 
 
 
 
 
INTRODUCTION 
 
 
 
 
1.1 Preface 
 
 
The biopharmaceutical industry has experienced a significant transformation 
based on the development of recombinant DNA and hybridoma technologies in the 
1970s.  The industry has moved beyond simple replication of human proteins (such 
as insulin or growth hormones) and played a key role in the development of large-
molecule drugs such as any protein, virus, therapeutic serum, vaccine, and blood 
component.  These genetically engineered therapeutic drugs are targeting some of the 
major illnesses such as cancer, cardiovascular, and infectious diseases and they have 
the full potential to tackle a whole array of new diseases effectively and safely. 
 
 
By mid 2003, 148 biopharmaceuticals proteins were approved in the United 
States and Europe compared to 84 in 2000 (Birch and Onakunle, 2005).  The total 
global market for protein drugs was $47.4 billion in 2006 and the market is presumed 
to reach $55.7 billion by the end of 2011 with an average annual growth rate 
(AAGR) of 3.3% (Figure 1.1).  It is expected that current cell culture facilities are 
unlikely to meet expected demand.  The imbalance of supply-demand is  
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expected to get worse in the future, as more biotech therapeutics proteins are 
approved.  20–50% of potential therapeutics could be delayed due to the lack of 
manufacturing capacity (Fernandez et al., 2002).  Hence, the ability in expanding the 
existing capacity and producing a larger variety of products are crucial in order to 
meet future demand.  Drug companies and biotech firms are considering alternative 
manufacturing platforms, besides increasing fermentation capacity (Table 1.1) 
(Elbehri, 2005). 
  
 
 
Figure 1.1: Worldwide sales forecast for protein drugs, 2006 and 2011 (Talukder, 
2007). 
 
 
Generally, recombinant therapeutic protein can be generated and produced in 
various prokaryotic and eukaryotic expression systems.  Until the early 1990s, the 
majority of recombinant proteins were expressed in either microbial or mammalian 
cell culture systems.  The first approved recombinant therapeutic glycoproteins, 
insulin is produced from Escherichia coli.  Today, the manufacturing of 
biotechnology products relies heavily on the use of mammalian cells, chiefly on 
Chinese Hamster Ovary (CHO) cells.  The well-known drugs Avonex (interferon 
beta 1-a, Biogen, Inc) and EPOGEN/EPREX (epoetin alfa, Amgen Inc/ Ortho 
Biotech) are produced in CHO.  Insect, transgenic plant, transgenic animal and yeast 
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cells are also attractive as hosts for the production of recombinant proteins, as they 
represent potentially inexpensive and versatile expression systems.  Optimal 
expression system can be varied, based on different critical parameters of the protein 
of interest.  Selecting an appropriate expression system for the protein of interest will 
affect factors such as time to market, cost of goods, product characteristics, 
regulatory hurdles, and intellectual property (Figure 1.2). 
 
 
Table 1.1: Comparison of pharmaceutical expression system (Elbehri, 2005). 
Expression 
System Advantages Disadvantages Applications 
Cost 
per 
gram 
Bacteria 
Established regulatory 
track; well-understood 
genetics; cheap and 
easy to grow 
Proteins not usually 
secreted; contain 
endotoxins; no 
posttranslational 
modifications 
Insulin (E. coli; Eli 
Lilly); growth 
hormone 
(Genentech); growth 
factor; interferon 
N.R 
Yeast 
Recognized as “safe;” 
long history of use; 
fast; inexpensive; 
posttranslational 
modifications 
Overglycosylation can ruin 
bioactivity; safety; potency; 
clearance; contains 
immunogens/antigens 
Beer fermentation; 
recombinant 
vaccines; hepatitis B 
viral vaccine; human 
insulin 
$50-
100 
Insect cells 
Posttranslational 
modifications; 
properly folded 
proteins; fairly high 
expression levels 
Minimal regulatory track; 
slow growth; expensive 
media; baculovirus 
infection (extra step); 
mammalian virus can infect 
cells 
Relatively new 
medium; Novavax 
produces virus-like 
particles 
N.R 
Mammalian 
cells 
 
Usually fold proteins 
properly; correct 
posttranslation 
modifications; good 
regulatory track 
record; only choice for 
largest proteins 
Expensive media; slow 
growth; may contain 
allergens/ contaminants; 
complicated purification 
Tissue plasminogen 
activator; factor VIII 
(glycoprotein); 
monoclonal 
antibodies 
(Hercepin) 
$500–
5,000 
Transgenic 
animals 
 
Complex protein 
processing; very high 
expression levels; easy 
scale up; low-cost 
production 
Little regulatory 
experience; potential for 
viral contamination; long 
time scales; isolation/GMPs 
on the farm 
Lipase (sheep, 
rabbits; PPL 
Therapeutics); 
growth hormone 
(goats; Genzyme); 
factor VIII (cattle) 
$20–
50 
Transgenic 
plants 
 
Shorter development 
cycles; easy seed 
storage/scaling; good 
expression levels; no 
plant viruses known to 
infect humans  
Potential for new 
contaminants (soil fungi, 
bacteria, pesticides); 
posttranslational 
modifications; contains 
possible allergens  
Cholera vaccine 
(tobacco; 
Chlorogen, Inc.); 
gastric lipase (corn; 
Meristem); hepatitis 
B (potatoes; Boyce 
Thompson) 
$10–
20 
N.R- Not Reported 
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The baculovirus expression vector system (BEVS) has a number of 
significant advantages over other methods of recombinant protein production.  It is 
best known as providing quick access to biologically active proteins and used as a 
research tool (Cox, 2004).  The major advantages of BEVS over bacterial and 
mammalian expression system is the very high expression of recombinant proteins 
which in many cases are antigenically, immunogenically and functionally similar to 
their native counterparts (Goosen, 1993).  Lack of adventitious viral agents that 
could replicate in mammalian cells (John Morrow, 2007), make BEVS a powerful 
manufacturing platform for health care solutions to pandemic, biodefense, and 
emergency scenarios (Cox, 2004).  However, BEVS also has its limitation in 
producing authentic mammalian proteins and glycoproteins.  An absence of complex 
sugars in BEVS-produced proteins may result in poor pharmacological activity in 
vivo due to the rapid clearance from the circulatory system of glycoproteins with 
non-human glycans (Betenbaugh et al., 2004)  
 
 
 
Figure 1.2: Strength and weaknesses of various expression systems (Cox, 2004). 
 
 
The deficiency of BEVS in producing mammalian like-glycoproteins of 
potential therapeutic is a hot topic among researchers in this field.  BEVS had been 
reported to produce sialylated complex type N-glycan through the modification of its 
metabolic engineering pathway (Betenbaugh et al., 2004; Viswanathan et al., 2005; 
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Yun et al., 2005).  Protein Sciences Corporation (PSC) had developed technology for 
large-scale (600 L) production of proteins in insect cells using the BEVS (Cox, 
2004).  Although currently there are no FDA-approved therapeutic proteins 
expressed using BEVS, a number of products are in advanced clinical trials and 
several are about to get acceptance.  Among these, three vaccines that are close to 
market are Provenge™, a prostate cancer immunotherapy from Dendreon 
(www.dendreon.com); Ceravix™, a papilloma virus vaccine from GlaxoSmithKline 
(www.gsk.com); and FluBIOk™ from Protein Sciences, a non-egg based flu vaccine 
(John Marrow, 2007).   
 
 
BEVS have tremendous potential to become the next therapeutic 
manufacturing system.  In this study, recombinant human transferrin was used as a 
model protein.  Transferrin was chosen because of the simplicity of its structure and 
its recent important role in protein engineering.  Non-glycosylated transferrin had 
been used as a scaffold to extend the half life of peptide and proteins.  Various 
chromatographic methods for purification of transferrin have been reported.  Among 
these reports, Ali et al. (1996) and Ailor et al. (2000) had purified rhTf from sf9 and 
Tn cells using phenyl sepharose and Q-Sepharose.  In this study, hydrophobic 
interaction chromatography utilizing phenyl sepharose was used as the capture step 
and IEX chromatography utilizing Q-sepharose was used for further purification of 
rhTf.  To obtain pure rtTf, optimization of both chromatographic techniques had 
been carried out. Basic characterization of the carbohydrate content of the pure rhTf 
had also been carried out to get a better understanding of the glycan.   
 
 
 
 
 
 
 
 
 
 
 6
1.2 Objectives 
 
 
The objective of this work was to optimize the chromatographic purification 
process of recombinant human transferrin expressed using BEVS to obtain pure rhTf 
in improved yield and recovery.   
 
 
. 
 
1.3 Scopes of Research 
 
 
The following are the scopes of this work: 
1) Propagation of baculovirus. 
2) Small scale production of rhTf using optimized medium. 
3) Characterization of productivity profiles using SDS-PAGE, ELISA and Western 
Blot. 
4) Optimization of purification process of rhTf using HIC and IEX.  
5) Characterization of the monosaccharide composition of the expressed rhTf. 
 
